Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals Statistics
Share Statistics
Centessa Pharmaceuticals has 132.63M shares outstanding. The number of shares has increased by 33.29% in one year.
| Shares Outstanding | 132.63M |
| Shares Change (YoY) | 33.29% |
| Shares Change (QoQ) | 16.33% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 80.34M |
| Failed to Deliver (FTD) Shares | 492 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 3.29M, so 2.5% of the outstanding shares have been sold short.
| Short Interest | 3.29M |
| Short % of Shares Out | 2.5% |
| Short % of Float | 3.65% |
| Short Ratio (days to cover) | 6.42 |
Valuation Ratios
The PE ratio is -8.13 and the forward PE ratio is -10.71. Centessa Pharmaceuticals's PEG ratio is -0.26.
| PE Ratio | -8.13 |
| Forward PE | -10.71 |
| PS Ratio | 0 |
| Forward PS | 4.1 |
| PB Ratio | 4.78 |
| P/FCF Ratio | -13.49 |
| PEG Ratio | -0.26 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Centessa Pharmaceuticals.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.25, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.25 |
| Quick Ratio | 9.25 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.02 |
| Cash Flow / Debt | -17.14 |
| Interest Coverage | 19.93 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -49.66%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -49.66% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3,061,779.22 |
| Employee Count | 77 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.84M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 28.41% in the last 52 weeks. The beta is 1.55, so Centessa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | 28.41% |
| 50-Day Moving Average | 16.45 |
| 200-Day Moving Average | 14.63 |
| Relative Strength Index (RSI) | 38.16 |
| Average Volume (20 Days) | 890.84K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -201.06M |
| Net Income | -235.76M |
| EBITDA | -201.06M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.06 |
Balance Sheet
The company has 383.22M in cash and 8.29M in debt, giving a net cash position of 374.94M.
| Cash & Cash Equivalents | 383.22M |
| Total Debt | 8.29M |
| Net Cash | 374.94M |
| Retained Earnings | -988.7M |
| Total Assets | 576.8M |
| Working Capital | 478.41M |
Cash Flow
In the last 12 months, operating cash flow was -142.06M and capital expenditures -34K, giving a free cash flow of -142.09M.
| Operating Cash Flow | -142.06M |
| Capital Expenditures | -34K |
| Free Cash Flow | -142.09M |
| FCF Per Share | -1.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.2% |
| FCF Yield | -7.38% |
Analyst Forecast
The average price target for CNTA is $27.5, which is 89.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.5 |
| Price Target Difference | 89.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 4.5 |
| Piotroski F-Score | 2 |